Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Leukemia
11:02

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Prednisone for BCR-ABL1+ ALL and Blast Phase CML in Adults"

FEATURING Marlise R. Luskin
  • 196 views
  • December 20, 2023
07:33

ecancer

Epitope Editing Enables Targeted Immunotherapy of AML

FEATURING Gabriele Casirati
  • 14 views
  • October 23, 2023
10:42

ASH 2022 Conference Coverage

Results From the Phase 3 ALPINE Study: Zanubrutinib vs. Ibrutinib in R/R CLL & SLL

FEATURING Jennifer Brown
  • 194 views
  • April 14, 2023
04:14

ecancer

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for Treatment of R/R CLL and SLL

FEATURING Jennifer Brown
  • 499 views
  • January 11, 2023
  • 1
11:05

ASH 2022 Conference Coverage

ASH 2022 Preliminary Safety & Efficacy From the Phase 2 APEX Study of Bezuclastinib, a Novel, Highly Selective, Potent KIT D816V TKI, in Adults With Advanced Systemic Mastocytosis

FEATURING Daniel J. DeAngelo
  • 10 views
  • January 4, 2023
14:22

Dana-Farber Cancer Institute

FLT3 Mutations in AML: What Is the Benefit of Midostaurin for Upfront Use? Is There a Clinical Significance of FLT3 Inhibitors in Relapsed Disease?

FEATURING Richard Stone
  • 256 views
  • May 28, 2020
  • 2
15:59

Dana-Farber Cancer Institute

What's New in AML: Approach to Relapsed and Refractory Disease

FEATURING Marlise R. Luskin
  • 562 views
  • September 6, 2019
  • 1
12:14

Dana-Farber Cancer Institute

FDA Approval of Duvelisib for CLL

FEATURING Jennifer Brown
  • 460 views
  • December 20, 2018
  • 3
16:18

Dana-Farber Cancer Institute

What is Clonal Hematopoiesis and Why Does It Matter?

FEATURING David P. Steensma
  • 2,083 views
  • September 26, 2018
  • 12
05:22

Dana-Farber Cancer Institute

Ask the Experts: How I Treat CLL in 2018 Discussion

FEATURING Matthew Davids
  • 171 views
  • September 8, 2018
  • 1
23:36

Dana-Farber Cancer Institute

Approach to Frontline Treatment of CLL in 2018

FEATURING Matthew Davids
  • 603 views
  • September 8, 2018
  • 3
12:28

Dana-Farber Cancer Institute

CML Frontline Treatment Choice and Monitoring

FEATURING Daniel J. DeAngelo
  • 219 views
  • May 7, 2018
20:53

Dana-Farber Cancer Institute

Advances in the Use of Monoclonal Antibodies for ALL

FEATURING Daniel J. DeAngelo
  • 148 views
  • April 3, 2018
75:50

Dana-Farber Cancer Institute

Mapping the Future of Acute Lymphoblastic Leukemia

FEATURING Daniel J. DeAngelo
  • 208 views
  • January 8, 2018
  • 1
11:02

Dana-Farber Cancer Institute

FLT-3 Inhibitors in AML

FEATURING Richard Stone
  • 569 views
  • December 27, 2017
  • 1